

Frontotemporal Disorders Treatment Market - 2021

<https://marketpublishers.com/r/F6C77D00A861EN.html>

Date: May 2025

Pages: 220

Price: US\$ 2,999.00 (Single User License)

ID: F6C77D00A861EN

Abstracts

The Frontotemporal Disorders Treatment Market was valued at USD 721.4 million in 2021 and is anticipated to reach by , at a CAGR of 0.065 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Frontotemporal Disorders Treatment Market.

This report delivers a comprehensive overview of the Frontotemporal Disorders Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Frontotemporal Disorders Treatment Market. The Frontotemporal Disorders Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2021–.

Frontotemporal Disorders Treatment Market Scope:

Key Players

Apotex Inc.

Johnson & Johnson

Auro Pharma

Pfizer Inc.

Teva Pharmaceuticals USA, Inc.

AstraZeneca plc.

Mylan N.V.

Sanofi S.A.

Valeant Pharmaceutical International

Eli Lilly and Company

Major Highlights

This report delivers a comprehensive overview of the Frontotemporal Disorders Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Frontotemporal Disorders Treatment Market. The Frontotemporal Disorders Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2021–.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions

apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. MARKET DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Market Snippet by Drug Class
- 3.2. Market snippet by Indication
- 3.3. Market snippet by Distribution Channel
- 3.4. Market Snippet by Region

4. MARKET DYNAMICS

- 4.1. Market Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising Prevalence of Frontotemporal Disorders
 - 4.1.1.2. Increasing Funding by Government & Non-Government Organizations
 - 4.1.1.3. XX
 - 4.1.2. Restraints:
 - 4.1.2.1. High Cost of treatment
 - 4.1.2.2. XX
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Forces Analysis
- 5.2. Epidemiology
- 5.3. Pipeline Analysis
- 5.4. Supply Chain Analysis
- 5.5. Pricing Analysis
- 5.6. Regulatory Analysis
- 5.7. Unmet Needs
- 5.8. COVID-19 Impact Analysis

6. BY DRUG CLASS

6.1. Introduction

6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment

6.3. Market Attractiveness Index, By Drug Class Segment

6.3.1. Cognitive Enhancers*

6.3.1.1. Introduction

6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

6.3.2. Antipsychotics

6.3.2.1. Aripiprazole

6.3.2.2. Paliperidone

6.3.2.3. Olanzapine

6.3.2.4. Risperidone

6.3.2.5. Quetiapine

6.3.2.6. Ziprasidone

6.3.3. Antidepressants

6.3.3.1. Bupropion

6.3.3.2. Fluvoxamine

6.3.3.3. Citalopram

6.3.3.4. Fluoxetine

6.3.3.5. Mirtazepine

6.3.3.6. Paroxetine

6.3.3.7. Sertraline

6.3.4. CNS stimulants

6.3.5. Others

7. BY INDICATION

7.1. Introduction

7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

7.3. Market Attractiveness Index, By Indication Segment

7.3.1. Behaviour Variants Frontotemporal Dementia. (BFTD)*

7.3.1.1. Introduction

7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

7.3.2. Primary Progressive Aphasia (PPA)

7.3.2.1. Semantic PPA

7.3.2.2. Agrammatic PPA

7.3.2.3. Logopenic PPA

7.3.3. Motor Decline

7.3.3.1. Corticobasal syndrome (CBS)

7.3.3.2. Progressive supranuclear palsy (PSP)

8. BY DISTRIBUTION CHANNEL

8.1. Introduction

8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment

8.3. Market Attractiveness Index, By Distribution Channel Segment

8.3.1. Hospital Pharmacies*

8.3.1.1. Introduction

8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

8.3.2. Retail Pharmacies

8.3.3. Online Pharmacies

8.3.4. Others

9. BY REGION

9.1. Introduction

9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

9.1.2. Market Attractiveness Index, By Region

9.2. North America

9.2.1. Introduction

9.2.2. Key Region-Specific Dynamics

9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

9.2.6.1. The U.S.

9.2.6.2. Canada

9.2.6.3. Mexico

9.3. Europe

9.3.1. Introduction

9.3.2. Key Region-Specific Dynamics

9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

- 9.3.6.1. Germany
- 9.3.6.2. The U.K.
- 9.3.6.3. France
- 9.3.6.4. Italy
- 9.3.6.5. Spain
- 9.3.6.6. Rest of Europe
- 9.4. South America
 - 9.4.1. Introduction
 - 9.4.2. Key Region-Specific Dynamics
 - 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
 - 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 9.4.6.1. Brazil
 - 9.4.6.2. Argentina
 - 9.4.6.3. Rest of South America
- 9.5. Asia Pacific
 - 9.5.1. Introduction
 - 9.5.2. Key Region-Specific Dynamics
 - 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
 - 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
 - 9.5.6.1. China
 - 9.5.6.2. India
 - 9.5.6.3. Japan
 - 9.5.6.4. Australia
 - 9.5.6.5. Rest of Asia Pacific
- 9.6. The Middle East and Africa
 - 9.6.1. Introduction
 - 9.6.2. Key Region-Specific Dynamics
 - 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
 - 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
 - 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE

- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Apotex Inc.*

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. Johnson & Johnson

11.3. Auro Pharma

11.4. Pfizer Inc.

11.5. Teva Pharmaceuticals USA, Inc.

11.6. AstraZeneca plc.

11.7. Mylan N.V.

11.8. Sanofi S.A.

11.9. Valeant Pharmaceutical International

11.10. Eli Lilly and Company (LIST NOT EXHAUSTIVE)

12. DATAM INTELLIGENCE

12.1. Appendix

12.2. About Us and Services

12.3. Contact Us

I would like to order

Product name: Frontotemporal Disorders Treatment Market - 2021

Product link: <https://marketpublishers.com/r/F6C77D00A861EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F6C77D00A861EN.html>